5/21/2023 0 Comments AMVAD by Axael GD![]() Vaccines against bacterial and viral pathogens affecting the respiratory system, such as tuberculosis, streptococcal pneumonia, and influenza.The NRC has developed a novel archaeal polar lipid mucosal vaccine adjuvant and delivery (AMVAD) platform capable of generating mucosal and systemic immune responses against a wide range of pathogens that infect mucosal surfaces or use them to gain entry to the body. There is thus a demand for safe, effective, non-replicating mucosal adjuvants and vaccines capable of preventing respiratory infections such as tuberculosis, streptococcal pneumonia, and influenza, as well as sexually transmitted infections such as HIV and genital Chlamydia. ![]() The majority of approved vaccines are administered systemically, and fail to elicit effective mucosal immunity. ![]() ![]() Many microbial pathogens invade their mammalian hosts through the mucosal surfaces of the respiratory, gastrointestinal and urogenital tracts. ![]()
0 Comments
Leave a Reply. |